HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

naproxen-n-butyl nitrate

a nitric oxide-releasing NSAID derivative
Also Known As:
4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl)propanoate; AZD 3582; AZD-3582; AZD3582; NO-naproxen; Naproxcinod; NicOx; nitric oxide naproxen; nitric oxide-releasing naproxen
Networked: 41 relevant articles (6 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Duquesroix, Brigitte: 5 articles (05/2011 - 09/2009)
2. Schnitzer, Thomas J: 5 articles (05/2011 - 12/2005)
3. Jonzon, Bror: 4 articles (03/2006 - 01/2003)
4. Frayssinet, Hayet: 3 articles (05/2011 - 12/2010)
5. Ongini, Ennio: 2 articles (01/2015 - 06/2014)
6. Miglietta, Daniela: 2 articles (01/2015 - 06/2014)
7. White, William B: 2 articles (05/2011 - 09/2009)
8. Pivodic, Aldina: 2 articles (05/2011 - 06/2009)
9. Beekman, Maarten: 2 articles (02/2011 - 09/2009)
10. Boring, Daniel: 2 articles (12/2010 - 11/2009)

Related Diseases

1. Pain (Aches)
09/01/2006 - "This study assessed the analgesic efficacy of single doses of 4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate (AZD3582) in acute postoperative dental pain after the removal of an impacted mandibular third molar (ie, wisdom tooth). "
09/01/2006 - "In the comparator study, AZD3582 750 mg was superior to placebo in "time to rescue medication (0-24 hours)" (HR [95% CI], 0.4 [0.3-0.6], P < 0.001), "time to confirmed perceptible pain relief" (2.1 [1.1-3.8], P = 0.02), and MPID (11.9 [4.2-19.5], P = 0.002). "
09/01/2006 - "In the dose-finding study, the AZD3582 750-, 1500-, and 2250-mg groups were superior to placebo in the primary variables "time to rescue medication (0-8 hours)" (hazard ratios [HRs] [95% CIs], 0.17 [0.07-0.42], P < 0.003; 0.23 [0.11-0.50], P < 0.001; and 0.15 [0.06-0.36], P < 0.001, respectively), "time to meaningful pain relief" (HRs [95% CIs], 3.42 [1.87-6.25], P < 0.003; 2.49 [1.37-4.50], P < 0.003; and 3.07 [1.70-5.55], P < 0.001, respectively), and MPID (analysis of covariance [ANCOVA] least squares mean [LSM] differences [95% CIs], 25.8 [17.3-34.4], P < 0.003; 20.4 [12.1-28.7], P < 0.003; and 29.3 [20.9-37.6], P < 0.001, respectively). "
11/01/2003 - "The potential combination of effective pain relief and gastrointestinal protection offered by AZD3582 warrants further evaluation in human clinical studies."
01/01/2003 - "Studies to evaluate the longer-term gastrointestinal safety of AZD3582, alongside its efficacy in alleviating chronic and acute pain, are ongoing."
2. Osteoarthritis
3. Knee Osteoarthritis
4. Inflammation
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. Naproxen (Naprosyn)
2. Nitric Oxide (Nitrogen Monoxide)
3. Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
4. rofecoxib (Vioxx)
5. Ibuprofen (Motrin)
6. Aspirin (Acetylsalicylic Acid)
7. nitroaspirin
8. Sirolimus (Rapamycin)
9. Citalopram (Escitalopram)
10. Sodium

Related Therapies and Procedures

1. Stents
2. Analgesia
3. Oral Administration